Wideblue design saves money during development of new drugs

01 July 2010

Biopta have published a paper describing an application of their unique PM-1 perfusion myograph instrument, which was designed and manufactured by Wideblue.

The PM-1 allows new drug candidates to be screened for adverse reactions at an early stage in drug development, resulting in better prediction of the safest and most effective drugs.

Wideblue
Skip to content